Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.

Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace

CALR mutation assay for MPN diagnosis, 2/17

February 2017—Qiagen announced the European launch of its CE-IVD marked calreticulin mutation assay to aid in establishing the diagnosis of myeloproliferative neoplasms. The ipsogen CALR RGQ PCR kit is intended for the detection of CALR mutations in genomic DNA from subjects suspected of myeloproliferative neoplasms. It enables identification of the two major CALR mutations, type 1 and type 2, and detects additional mutations in the CALR exon 9 region.

Test IDs patients who may benefit from olaparib, 2/17

February 2017—Myriad Genetics announced that its BRAC­Analysis CDx test accurately identified patients who may benefit from treatment with olaparib. The test was included in the SOLO2 study as a diagnostic with olaparib, an oral PARP inhibitor being developed by AstraZeneca.

Horizon, CareDx enter into OEM agreement, 2/17

February 2017—Horizon Discovery Group has entered into an original equipment manufacturer agreement with CareDx. Under the terms of the new agreement, Horizon will supply cell-free DNA-based molecular reference standards for inclusion in CareDx’s cfDNA testing workflows for monitoring transplanted organ rejection.

FDA clears strep assay , 2/17

February 2017—Quidel has received 510(k) clearance from the Food and Drug Administration to market its Solana Strep Complete Assay for the rapid and qualitative detection and differentiation of Streptococcus pyogenes (group A beta-hemolytic streptococcus) and Streptococcus dysgalactiae (pyogenic group C and G beta-hemolytic streptococcus) nucleic acids isolated from throat swab specimens obtained from symptomatic patients.

Rapid test for emergency evaluation of sepsis, 2/17

February 2017—Nanomix released a rapid diagnostic test panel designed to quickly evaluate patients affected by sepsis and that runs on Nanomix eLab, the company’s handheld diagnostic system. Designed for emergency medical and other point-of-care needs, the test uses a single patient blood, plasma, or serum sample to provide actionable results within 10 minutes.

Streck adds Makler to sperm count assays, 2/17

February 2017—Streck’s Sperm-Chex and Sperm-Chex Post VC, both with stabilized sperm cells, are now assayed for the Makler Counting Chamber. Sperm-Chex has two clinically significant levels of control to simulate the sperm cell concentration that technologists encounter in patient samples. It has the same chamber loading and optical characteristics as a patient sample. Sperm-Chex verifies the sperm analysis process and tests the technologist’s proficiency in sperm cell quantification and qualification.

Liquid biopsy system, 2/17

February 2017—WaveSense introduced its nRichDX system for the bulk isolation of target cells and nucleic acids from liquid biopsies. The nRichDX uses the company’s proprietary paramagnetic bead technology to enable the capture of circulating tumor cells and cell-free DNA or cell-free RNA in quantities sufficient for analysis by next-generation sequencing and PCR techniques.

Trovagene, Boreal Genomics strategic partnership, 2/17

February 2017—Trovagene has entered into a long-term supply and distribution agreement with Boreal Genomics in which they will merge their respective technologies to co-develop urine and blood ctDNA assay kits. The companies intend to address an unmet need in the liquid biopsy testing market by providing a simple, routine, and low-cost urine and blood ctDNA assay for next-generation sequencing platforms run by laboratories of research institutions, cancer centers, and service facilities around the world.

MARKETPLACE

TRENDING